argenx SEARGX -0.17%80 Interest Coverage is 394.00 as of Mar. 2026, which is 96% below its 10-year median of 10,000.00. GuruFocus rates ARGX with a GF Score™ of 80/100 and a GF Value™ of $1,363.68 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 377 Biotechnology companies, argenx SE ranks better than 56.23% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. argenx SE's
Operating Income
for the
three
months ended in Mar. 2026 was $394 Mil. argenx SE's Interest Expense for the
three
months ended in Mar. 2026 was $-1 Mil.
argenx SE's interest coverage for the quarter that ended in Mar. 2026 was 394.00.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. argenx SE has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for argenx SE's Interest Coverage or its related term are showing as below:
ARGX'
s Interest Coverage Range Over the Past 10 Years
Min: 258.36 Med: No Debt Max: No Debt
Current: 320.34
ARGX's Interest Coverage is ranked better than 56.23% of 377
companies
in the Biotechnology industry
Industry Median: 106.07
vs ARGX: 320.34
argenx SE (NAS:ARGX) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
argenx SE Interest Coverage Related Terms
argenx SE Interest Coverage Historical Data
* Premium members only.
The historical data trend for argenx SE's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ARGX vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, argenx SE's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
argenx SE Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, argenx SE's Interest Coverage distribution charts can be found below:
* The bar in red indicates where argenx SE's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
argenx SE (ARGX) has a Interest Coverage of 394.00 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on argenx SE and its competitors. This is 96% below median its historical median of 10,000.00. Over the past decade, argenx SE's Interest Coverage has ranged from 258.36 to 10,000.00. According to the industry distribution chart, argenx SE ranks #165 out of 377 companies in the Biotechnology industry, placing it in the top 43.8%.
Is argenx SE's Interest Coverage too high?
argenx SE's current Interest Coverage of 394.00 is 96% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 258.36 to a high of 10,000.00. The Biotechnology industry median Interest Coverage is 106.07. argenx SE's value of 394.00 is 271.5% above this industry median. Based on the distribution chart, argenx SE ranks #165 out of 377 companies in the Biotechnology industry, which is above the industry midpoint. Overall, argenx SE has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does argenx SE's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, argenx SE ranks #165 out of 377 companies for Interest Coverage. This puts argenx SE in the upper half of its industry. The industry median Interest Coverage is 106.07. argenx SE's value of 394.00 is 271.5% above this benchmark. Historically, argenx SE's own Interest Coverage has ranged from 258.36 to 10,000.00 over the past decade. While the company's 10-year median is 10,000.00 vs. the industry median of 106.07, argenx SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. argenx SE's current Interest Coverage of 394.00 is 271.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on argenx SE and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. argenx SE's current Interest Coverage is 394.00, which is 96% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
Based on GuruFocus' analysis, argenx SE (ARGX) is currently considered Significantly Undervalued. The stock's GF Value™ is $1,363.68, compared to a current price of $885.80 — trading 35% below its estimated fair value. The current Interest Coverage is 394.00, which is 96% below median its 10-year median of 10,000.00 and 271.5% above the Biotechnology industry median of 106.07. argenx SE's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For argenx SE (ARGX), the current Interest Coverage is 394.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is argenx SE (ARGX) Overvalued in 2026?
Based on GuruFocus' analysis, argenx SE stock appears to be undervalued.
The current stock price of $885.80 is trading 35% below its estimated GF Value™ of $1,363.68.
GuruFocus considers argenx SE to be Significantly Undervalued.
Key valuation signals for ARGX:
Interest Coverage: 394.00 (96% below median its 10-year median of 10,000.00)
GF Value™: $1,363.68 vs. price of $885.80 (35% below fair value)
Industry Position: 271.5% above the Biotechnology median (#165 of 377)
No single metric tells the full story. See the ARGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
80GF Score
Get the complete analysis for ARGX
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARGX has been successfully added to your 
